Trial backs Lilly’s Olumiant plus remdesivir as combo COVID-19 therapy
pharmaphorum
SEPTEMBER 16, 2020
Adding Eli Lilly’s rheumatoid arthritis drug Olumiant (baricitinib) and Gilead Sciences’ remdesivir reduces recovery time in COVID-19 patients compared to remdesivir alone, says a new trial. ACTT-2 used a 4mg dose of the drug, which wasn’t approved by the FDA on safety grounds.
111 
Let's personalize your content